Compare Amgen, Inc. (AMGN) vs Kraft Heinz Co (KHC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Kraft Heinz Co — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Kraft Heinz Co trades at $24.9 (market cap $29.47B). The key difference: Amgen, Inc. is far larger — about 6.7× Kraft Heinz Co's market cap, and Kraft Heinz Co pays the higher dividend (6.44%). Which is the better fit depends on your goals.
| AMGN | KHC | |
|---|---|---|
Market Cap | $196.12B | $29.47B |
Sector | Health | Consumer Staples |
52-Week High | $388.16 | $28.94 |
52-Week Low | $271.18 | $21.21 |
Enterprise Value | $241.41B | $46.51B |
Dividend Yield | 2.77% | 6.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Kraft Heinz (KHC) trades at $24.85, up 0.69% with bullish technical momentum including a golden cross formation. The company shows mixed fundamentals with strong cash flow generation ($4.46B operating cash flow in 2025) but negative profitability metrics (-23.05% net margin). Recent earnings beats and a 6.4% dividend yield provide support, while the company's global reorganization aims to accelerate growth. Technical indicators show bullish moving averages with neutral oscillators, trading near key resistance at $25.
KHC presents a value opportunity with attractive valuation (P/E 13.04, P/B 0.7) and high dividend yield, but faces significant profitability challenges. The stock's upside depends on successful execution of restructuring initiatives and margin improvement. Key risks include persistent negative earnings, competitive pressures, and execution missteps in the new operating structure. Analyst consensus remains cautious with only 11% buy ratings despite recent positive technical momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →
